PubRank

Klaus Strebel

Author PubWeight™ 84.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003 4.23
2 HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008 3.72
3 Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 2009 3.47
4 Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 2003 3.05
5 A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 2004 2.99
6 Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004 2.80
7 Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 2006 2.58
8 Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 2005 2.29
9 The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009 2.11
10 Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 2007 2.03
11 Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 2003 2.00
12 Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 2008 1.86
13 Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog 2010 1.66
14 CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol 2010 1.63
15 Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 2006 1.60
16 Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol 2013 1.58
17 Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 2004 1.56
18 Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci 2002 1.54
19 Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 2007 1.53
20 Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 2007 1.52
21 Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol 2003 1.49
22 Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 2007 1.48
23 HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2007 1.40
24 Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 2010 1.37
25 High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem 2004 1.34
26 Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 2003 1.32
27 The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect 2003 1.24
28 Stably expressed APOBEC3F has negligible antiviral activity. J Virol 2010 1.15
29 Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 2004 1.13
30 HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med 2010 1.09
31 Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol 2010 1.06
32 Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. J Biol Chem 2004 1.05
33 A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods 2005 1.04
34 HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 2007 1.03
35 Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog 2010 1.03
36 Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirology 2012 1.02
37 C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem 2011 1.01
38 Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1. J Virol 2008 1.00
39 Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J Virol 2010 1.00
40 The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res 2010 0.98
41 Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo. J Virol 2011 0.97
42 Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 2007 0.96
43 Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 2013 0.95
44 Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. J Virol 2008 0.94
45 Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol 2007 0.91
46 Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol 2002 0.91
47 APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages. Virology 2008 0.91
48 Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 2009 0.89
49 Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach. Front Microbiol 2011 0.87
50 Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells. J Virol 2011 0.82
51 The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release. J Biol Chem 2012 0.81
52 Hydrodynamic and functional analysis of HIV-1 Vif oligomerization. Biochemistry 2012 0.81
53 CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G. J Virol 2014 0.80
54 Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G. PLoS One 2012 0.80
55 Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. J Clin Invest 2016 0.79
56 A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes. J Virol 2012 0.76
57 Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions. J Virol 2013 0.76
58 HIV-1 accessory proteins: Vpu and Vif. Methods Mol Biol 2014 0.75
59 Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS 2015 0.75